Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

101.07USD
22 Oct 2014
Price Change (% chg)

$0.71 (+0.71%)
Prev Close
$100.36
Open
$101.10
Day's High
$101.15
Day's Low
$100.53
Volume
371,485
Avg. Vol
2,092,879
52-wk High
$108.77
52-wk Low
$86.09

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.59
Market Cap (Mil.): $283,044.00
Shares Outstanding (Mil.): 2,820.29
Dividend: 0.70
Yield (%): 2.79

Financials

  JNJ.N Industry Sector
P/E (TTM): 16.63 32.90 33.54
EPS (TTM): 6.03 -- --
ROI: -- 18.34 17.61
ROE: -- 19.01 18.42
Search Stocks

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

3:49pm IST

J&J, GSK ready to collaborate on Ebola vaccine work

LONDON, Oct 22 - Drugmakers will work together to accelerate development of an Ebola vaccine and Johnson & Johnson and GlaxSmithKline, both of which have experimental vaccine candidates, have already discussed collaboration.

3:41pm IST

UPDATE 1-J&J aims for 1 million Ebola vaccine doses in 2015

* Companies racing to develop first approved Ebola vaccine

12:43pm IST

J&J and Bavarian Nordic expand production of an Ebola vaccine program

- Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

11:55am IST

J&J and Bavarian Nordic expand production of an Ebola vaccine program

Oct 22 - Johnson & Johnson said it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program.

11:49am IST

Jury deliberations begin in first trial over DePuy's Pinnacle hips

- A lawyer for a Montana woman on Tuesday urged jurors in a U.S. court to find Johnson & Johnson's DePuy Orthopedics unit liable for failing to warn patients that metal-on-metal Pinnacle hip implants were defective at the close of the first trial over the device.

4:56am IST

Jury deliberations begin in first trial over DePuy's Pinnacle hips

Oct 21 - A lawyer for a Montana woman on Tuesday urged jurors in a U.S. court to find Johnson & Johnson's DePuy Orthopaedics unit liable for failing to warn patients that metal-on-metal Pinnacle hip implants were defective at the close of the first trial over the device.

4:46am IST

RPT-Tens of thousands expected to get Ebola vaccines from January - WHO

GENEVA, Oct 21 - Tens of thousands of people in West Africa are expected to begin getting experimental Ebola vaccines from January, but population-wide immunisation is still far off, the World Health Organization (WHO) said on Tuesday.

21 Oct 2014

Tens of thousands expected to get Ebola vaccines from January - WHO

GENEVA, Oct 21 - Tens of thousands of people in West Africa are expected to begin getting experimental Ebola vaccines from January, but population-wide immunisation is still far off, the World Health Organization (WHO) said on Tuesday.

21 Oct 2014

J&J beats forecasts, helped by hepatitis drug

REUTERS - Johnson & Johnson reported strong quarterly earnings on surging sales of a new treatment for hepatitis C, but the company said it had sharply reduced prices for its artificial hips and warned that profits could be hurt next year by the stronger dollar.

14 Oct 2014

Earnings vs. Estimates

Search Stocks